223 related articles for article (PubMed ID: 27282264)
1. Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma.
Kim JH; Sinn DH; Kim K; Kim H; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Gut Liver; 2016 Nov; 10(6):939-947. PubMed ID: 27282264
[TBL] [Abstract][Full Text] [Related]
2. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
Lim YS; Han S; Heo NY; Shim JH; Lee HC; Suh DJ
Gastroenterology; 2014 Jul; 147(1):152-61. PubMed ID: 24583062
[TBL] [Abstract][Full Text] [Related]
3. Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B.
Kim HS; Kim BK; Kim SU; Park JY; Kim DY; Song KJ; Park JW; Kim YJ; Baatarkhuu O; Han KH; Ahn SH
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1647-1656.e6. PubMed ID: 27305847
[TBL] [Abstract][Full Text] [Related]
4. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
[TBL] [Abstract][Full Text] [Related]
5. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
6. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
Shin HS; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Baatarkhuu O; Ahn SH
J Gastroenterol Hepatol; 2012 Sep; 27(9):1528-34. PubMed ID: 22497450
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Nikolopoulou G; Raptopoulou-Gigi M; Gogos C; Vafiadis-Zouboulis I; Karamanolis D; Chouta A; Ilias A; Drakoulis C; Mimidis K; Ketikoglou I; Manesis E; Mela M; Hatzis G; Dalekos GN;
J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
Kuzuya T; Katano Y; Kumada T; Toyoda H; Nakano I; Hirooka Y; Itoh A; Ishigami M; Hayashi K; Honda T; Goto H
J Gastroenterol Hepatol; 2007 Nov; 22(11):1929-35. PubMed ID: 17914972
[TBL] [Abstract][Full Text] [Related]
10. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
11. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Lee KK; Wu DB; Chow PY; Lee VW; Li H
J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
[TBL] [Abstract][Full Text] [Related]
12. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study.
Qi W; Shen J; Dai J; Wu Y; Zhang Y; Leng S; Gao F; Ran S; Peng W; Zhang X; Wen T; Li C
Cancer Med; 2021 Dec; 10(23):8421-8431. PubMed ID: 34643050
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
[TBL] [Abstract][Full Text] [Related]
14. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation.
Hsu YC; Mo LR; Chang CY; Perng DS; Tseng CH; Lo GH; Tai CM; Lin CW; Hsu CC; Hsu CY; Huang SC; Lin JT
Antivir Ther; 2012; 17(4):605-12. PubMed ID: 22301517
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients.
Li X; Zhong X; Chen ZH; Xing YF; Wu DH; Chen J; Ma XK; Lin Q; Wen JY; Wei L; Wang TT; Ruan DY; Lin ZX; Wu XY; Dong M
Asian Pac J Cancer Prev; 2014; 15(22):9635-41. PubMed ID: 25520081
[TBL] [Abstract][Full Text] [Related]
16. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
[TBL] [Abstract][Full Text] [Related]
17. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH
Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
[TBL] [Abstract][Full Text] [Related]
18. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.
Wong GL; Chan HL; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Lai JW; Lo AO; Chan HY; Wong VW
Hepatology; 2013 Nov; 58(5):1537-47. PubMed ID: 23389810
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues.
Toyoda H; Kumada T; Tada T; Sone Y; Fujimori M
J Vasc Interv Radiol; 2012 Mar; 23(3):317-22.e1. PubMed ID: 22265248
[TBL] [Abstract][Full Text] [Related]
20. Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
Boettler T; Thimme R
Dig Dis; 2015; 33(4):608-12. PubMed ID: 26159281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]